<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2024-14-4-298-311</article-id><article-id custom-type="edn" pub-id-type="custom">YEAFRC</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1826</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Степени тяжести постковидного синдрома у реконвалесцентов COVID-19 и их ассоциации с основными факторами риска хронических неинфекционных заболеваний</article-title><trans-title-group xml:lang="en"><trans-title>Severity of Postcovid Syndrome in Convalescent Covid-19 and Their Association with the Main Risk Factors for Chronic Non-Communicable Diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0423-5021</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Карасева</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Karaseva</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Карасева Александра Александровна — Младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Alexandra A. Karaseva — Junior Researcher of the Laboratory of Genetic and Environmental Determinants of the Human Life Cycle</p><p>Novosibirsk</p></bio><email xlink:type="simple">Sas96@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7875-1566</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Афанасьева</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Afanaseva</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Афанасьева Алёна Дмитриевна — к.м.н., зав. лабораторией генетических и средовых детерминант жизненного цикла человека</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Alena D. Afanaseva — candidate of medical sciences, head. Laboratory of Genetic and Environmental Determinants of the Human Life Cycle</p><p>Novosibirsk</p></bio><email xlink:type="simple">alene.elene@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5316-4664</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гарбузова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Garbuzova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гарбузова Евгения Витальевна — к.м.н., Научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Evgenia V. Garbuzova — Candidate of Medical Sciences, Researcher at the Laboratory of Genetic and Environmental Determinants of the Human Life Cycle</p><p>Novosibirsk</p></bio><email xlink:type="simple">stryukova.j@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3502-7599</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецов Александр Александрович — д.м.н., ведущий научный сотрудник лаборатории молекулярно-генетических исследований терапевтических заболеваний</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Aleksandr A. Kuznetsov — Doctor of Medical Sciences, leading researcher at the Laboratory of Molecular Genetic Research of Therapeutic Diseases</p><p>Novosibirsk</p></bio><email xlink:type="simple">uznetsoviimed@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9404-6987</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Палехина</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Palekhina</surname><given-names>Yu. Y.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Палехина Юлия Юрьевна — Младший научный сотрудник</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Yulia Yu. Palekhina — Junior Researcher</p><p>Novosibirsk</p></bio><email xlink:type="simple">ukolova@hotmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3465-7572</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щепина</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shchepina</surname><given-names>Yu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Щепина Юлия Владимировна — Научный сотрудник</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Yulia V. Shchepina — Researcher</p><p>Novosibirsk</p></bio><email xlink:type="simple">yulia@shchepin.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0436-2549</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шрамко</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shramko</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шрамко Виктория Сергеевна — к.м.н., професор, научный сотрудник, заведующая отделением клинико-биохимических и молекулярно-генетических методов исследований</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Victoria S. Shramko — Candidate of Medical Sciences, Professor, Researcher, Head of the Department of Clinical, Biochemical and Molecular Genetic Research Methods</p><p>Novosibirsk</p></bio><email xlink:type="simple">nosova@211.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1348-0253</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Логвиненко</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Logvinenko</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Логвиненко Ирина Ивановна — д.м.н., профессор, главный научный сотрудник лаборатории профилактической медицины, заместитель руководителя по лечебной работе</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Irina I. Logvinenko — Doctor of Medical Sciences, Professor, Chief Researcher of the Laboratory of Preventive Medicine, Deputy Head for Medical Work</p><p>Novosibirsk</p></bio><email xlink:type="simple">111157@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4936-8362</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рагино</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ragino</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рагино Юлия Игоревна — член-корреспондент РАН, д.м.н., профессор, руководитель НИИТПМ — филиал ИЦиГ СО РАН, главный научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний</p><p>Новосибирск</p></bio><bio xml:lang="en"><p>Yulia I. Ragino — Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Head of NIITPM — branch of the Institute of Cytology and Genetics SB RAS, chief researcher of the laboratory of clinical biochemical and hormonal studies of therapeutic diseases</p><p>Novosibirsk</p></bio><email xlink:type="simple">ragino@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт терапии и профилактической медицины — филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики СО РАН»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Internal and Preventive Medicine — Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences” (IIPM — Branch of IC&amp;G SB RAS)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>08</month><year>2024</year></pub-date><volume>14</volume><issue>4</issue><fpage>298</fpage><lpage>311</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Карасева А.А., Афанасьева А.Д., Гарбузова Е.В., Кузнецов А.А., Палехина Ю.Ю., Щепина Ю.В., Шрамко В.С., Логвиненко И.И., Рагино Ю.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Карасева А.А., Афанасьева А.Д., Гарбузова Е.В., Кузнецов А.А., Палехина Ю.Ю., Щепина Ю.В., Шрамко В.С., Логвиненко И.И., Рагино Ю.И.</copyright-holder><copyright-holder xml:lang="en">Karaseva A.A., Afanaseva A.D., Garbuzova E.V., Kuznetsov A.A., Palekhina Y.Y., Shchepina Y.V., Shramko V.S., Logvinenko I.I., Ragino Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1826">https://www.medarhive.ru/jour/article/view/1826</self-uri><abstract><p>Цель исследования: оценить влияние основных факторов риска (ФР) хронических неинфекционных заболеваний (ХНИЗ) на степень тяжести постковидного синдрома (ПКС) у реконвалесцентов COVID-19.Материалы и методы: в обсервационное одномоментное исследование было включено 270 человек (из них 48,1 % мужчин, средний возраст 53,2±13,2 года), являющихся реконвалесцентами COVID-19. Пациенты были разделены на 3 группы в соответствии со степенью тяжести ПКС. В группу 1 вошли 79 человек с отсутствием ПКС, в группу 2 — 97 пациентов с легкой степенью тяжести ПКС, в группу 3 — 94 пациента со средней степенью тяжести ПКС. Всем пациентам было проведено стандартное общеклиническое и лабораторное обследование, антропометрия, эхокардиография (ЭхоКГ), оценивались данные анамнеза. Лица без ПКС были моложе, чем пациенты, страдающие ПКС (р=0,003). У пациентов, имеющих ПКС, в сравнении с лицами, у которых ПКС не развился, статистически значимо был выше уровень глюкозы и IgG в сыворотке крови, значения систолического артериального давления (САД) и диастолического артериального давления (ДАД), показатели индекса массы тела (ИМТ), окружности талии (ОТ) и индексов- триглицеридглюкозного индекса (ТГИ)/ОТ, ТГИ /ИМТ, индекса накопления липидов (LAP), индекса висцерального ожирения (VAI), количество пациентов, страдающих ожирением, и лиц, имеющих диастолическую дисфункцию левого желудочка (ДД ЛЖ). Пациенты со средней степенью тяжести ПКС чаще имели сердечно-сосудистые заболевания (ССЗ) до развития новой коронавирусной инфекции (НКИ).Результаты: Показатели объема форсированного выдоха за 1 первую секунду (ОФВ1 ) , форсированной жизненной емкости легких (ФЖЭЛ) были ниже при легкой и средней степени тяжести ПКС, по сравнению с лицами без него. Обнаружена прямая связь между наличием ПКС и уровнем глюкозы (r =3,138, р=0,000), ДД ЛЖ (r =2,876, р=0,008) в общей группе. У женщин данная ассоциация была выявлена только с наличием ДД ЛЖ (r=4,457, р=0,008), а у мужчин — с уровнем глюкозы (r =4,343, р=0,000), ОТ (r =1,068, р=0,060) и наличием ДД ЛЖ (r =3,377, р=0,033). Шанс наличия ПКС средней степени тяжести у мужчин и женщин был ассоциирован с уровнем глюкозы (r =1,537, р=0,001), VAI (r =1,256, р=0,005), САД (r =0,977, р=0,027), ССЗ до COVID-19 (r =0,465, р=0,036). А в группе мужчин данная ассоциация сохранялась только с уровнем глюкозы (r =2,357, р=0,004), индексом VAI (r =1,430, р=0,020) и наличием предшествующих ССЗ (r =0,160, р=0,014).Заключение: наличие ПКС у реконвалесцентов COVID-19 независимо от других факторов связано с уровнем глюкозы и наличием ДД ЛЖ. ПКС средней степени тяжести ассоциирован с повышением уровня глюкозы, САД, индекса VAI и наличием ССЗ до заболевания НКИ, при этом у мужчин ПКС средней степени тяжести в большей степени ассоциирован с кардиометаболическими факторами риска (ФР).</p></abstract><trans-abstract xml:lang="en"><p>The purpose of the study is to assess the impact of the main risk factors (RF) of chronic non-communicable diseases on the severity of the postCOVID-19 syndrome (PCS) in COVID-19 convalescents.Materials and methods: 270 persons (48.1 % of them men, mean age 53.2±13.2 years) were included in the one-time observational study and are COVID-19 convalescents. The patients were divided into three groups according to the severity of the PCS. Group 1 included 79 people with no PCS, group 2 included 97 patients with light PCS, group 3 included 94 patients with moderate PCS. All patients were given standard general clinical and laboratory examination, anthropometry, echocardiography, and anamnesis data were evaluated. Persons without PCS were younger than patients with PCS (р=0,003). In patients with PCS compared to persons who did not develop PCS, statistically signifi cantly higher levels of glucose and IgG in the blood serum, systolic blood pressure and diastolic blood pressure, body mass index (BMI) waist circumference (WC) and indexes: triglyceride-glucose index (TyG /WC), TyG /BMI, lipid accumulation product (LAP), visceral adiposity index (VAI), number of obese patients and persons with diastolic left ventricular dysfunction. Patients with moderate PCS were more likely to have cardiovascular disease before developing a new coronavirus infection.Results: The forced expiratory volume in 1 s (FEV1), forced vital lung capacity (FVC) scores were lower for mild to moderate PCS compared to persons without PCS. There is a direct relationship between the presence of PCS and glucose level (r =3,138, p=0,000), diastolic left ventricular dysfunction (r =2,876, p=0,008) in the general group. In women, this association was detected only with the presence of diastolic left ventricular dysfunction (r=4,457, p=0,008). In men with glucose (r =4,343, р=0,000), WC (r =1,068, р=0,060) и diastolic left ventricular dysfunction (r =3,377, р=0,033). The chance of having a moderate PCS in men and women was associated with glucose level (r =1.537, p=0.001), VAI (r =1.256, p=0.005), САД (r =0.977, p=0.027), CVD before COVID-19 (r=0.460.036). In the group of men this association was preserved only with the level of glucose (r =2,357, p=0,004), the index VAI (r =1,430, p=0,020) and the presence of preceding CVD (r =0,160, p=0,014).Conclusion: the presence of PCS in convalescents COVID-19 independently of other factors is due to the level of glucose and the presence of diastolic left ventricular dysfunction. PCS of moderate severity is associated with an increase in glucose, systolic blood pressure, VAI index, and the presence of CVD prior to COVID disease, with PCS of moderate severity more associated with cardio-metabolic risk factors in men.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>постковидный синдром</kwd><kwd>степень тяжести постковидного синдрома</kwd><kwd>реконвалесценты COVID-19</kwd><kwd>новая коронавирусная инфекция</kwd><kwd>ожирение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>post-COVID-19 syndrome</kwd><kwd>severity of the post-COVID-19 syndrome</kwd><kwd>convalescents COVID-19</kwd><kwd>new coronavirus infection</kwd><kwd>obesity</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено в рамках Бюджетной темы No 122031700115-7, при поддержке стипендии Президента РФ NoСП-2974.2022.4 и гранта правительства Новосибирской области, заявка № 39423 (2024 год).</funding-statement><funding-statement xml:lang="en">The study was carried out within the framework of Budget Topic No. 122031700115-7, with the support of the scholarship of the President of the Russian Federation NoSP-2974.2022.4 and a grant from the government of the Novosibirsk region, application No. 39423 (2024)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Soriano JB, Murthy S, Marshall JC, et al. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22(4): e102-e107. doi: 10.1016/S1473-3099(21)00703-9.</mixed-citation><mixed-citation xml:lang="en">Soriano JB, Murthy S, Marshall JC, et al. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22(4): e102-e107. doi: 10.1016/S1473-3099(21)00703-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. 2021; 75(10): e14357. doi: 10.1111/ijcp.14357.</mixed-citation><mixed-citation xml:lang="en">Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, et al. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. 2021; 75(10): e14357. doi: 10.1111/ijcp.14357.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021; 6(9): e005427. doi: 10.1136/bmjgh-2021-005427.</mixed-citation><mixed-citation xml:lang="en">Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021; 6(9): e005427. doi: 10.1136/bmjgh-2021-005427.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. и др. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)» (12 месяцев наблюдения). Российский кардиологический журнал. 2023; 28(1): 5270. https://doi.org/10.15829/1560-4071-2023-5270</mixed-citation><mixed-citation xml:lang="en">Arutyunov G.P., Tarlovskaya E.I., Arutyunov A.G., et al. Clinical features of post-COVID period. Results of an International Register “Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)” (12-month follow-up). Russian Journal of Cardiology. 2023;28(1):5270. https://doi.org/10.15829/1560-4071-2023-5270 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Погосова Н.В., Кучиев Д.Т., Попова А.Б., и др. Последствия COVID-19 на отдаленном этапе после госпитализации по данным клинико-инструментальных и лабораторных методов исследования. Кардиологический вестник. 2023;18(4):56–66. https://doi.org/10.17116/Cardiobulletin20231804156</mixed-citation><mixed-citation xml:lang="en">Pogosova NV, Kuchiev DT, Popova AB, et al. Clinical, instrumental and laboratory data on consequences of COVID-19 in delayed period after admission. Russian Cardiology Bulletin. 2023;18(4):56–66. https://doi.org/10.17116/Cardiobulletin20231804156 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Волкова М.В., Кундер Е.В., Постковидный синдром: клинические проявления, терапевтические возможности. Рецепт. 2023; 158-168. doi: 10.34883/pi.2023.26.2.002</mixed-citation><mixed-citation xml:lang="en">Volkova M.V., Kunder E.V. Postcovid Syndrome: Clinical Manifestations, Therapeutic Possibilities. Recipe. 2023; 26 (2): 158-168. doi: 10.34883/PI.2023.26.2.002 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Казаков С.Д., Каменских Е.М., Соколова Т.С. и др. Современная эпидемиология: вызовы общественного здравоохранения и возможности их решения (обзор литературы). Проблемы социальной гигиены, здравоохранения и истории медицины. 2023; 31(3): 368—378. doi: 10.32687/0869-866X-2023-31-3-368-378</mixed-citation><mixed-citation xml:lang="en">Kazakov S.D., Kamenskikh E.M., Sokolova T.S., et al. The presentday epidemiology: challenges of public health and possibilities to settle them: publications review. Problemi socialnoi gigieni, zdravookhranenia i istorii meditsini. 2023; 31(3): 368–378. doi: http://dx.doi.org/10.32687/0869-866X-2023-31-3-368-378 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Карасева А.А., Худякова А.Д., Гарбузова Е.В. и др. Степени тяжести постковидного синдрома: систематический обзор. Архивъ внутренней медицины. 2023; 13(6): 422-435. doi: 10.20514/2226-6704-2023-13-6-422-435.</mixed-citation><mixed-citation xml:lang="en">Karaseva A.A., Khudiakova A.D., Garbuzova E.V. et al. Severity of Postcovid Syndrome: A Systematic Review. The Russian Archives of Internal Medicine. 2023; 13(6): 422-435. DOI: 10.20514/2226-6704-2023-13-6-422-435. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clinical biochemistry. 2001; 34(7): 583-8. doi: 10.1016/s0009-9120(01)00263-6.</mixed-citation><mixed-citation xml:lang="en">Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clinical biochemistry. 2001; 34(7): 583-8. doi: 10.1016/s0009-9120(01)00263-6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dobiasova M., Frohlich J., Sedova M. et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of lipid research, 2011; 52 (3): 566–571. doi: 10.1194/jlr.P011668</mixed-citation><mixed-citation xml:lang="en">Dobiasova M., Frohlich J., Sedova M. et al. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. Journal of lipid research, 2011; 52 (3): 566–571. doi: 10.1194/jlr.P011668</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metabolic syndrome and related disorders. 2008;6(4):299-304. doi: 10.1089/met.2008.0034.</mixed-citation><mixed-citation xml:lang="en">Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metabolic syndrome and related disorders. 2008;6(4):299-304. doi: 10.1089/met.2008.0034.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng S, Shi S, Ren X, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. Journal of translational medicine. 2016 Sep 7; 14(1): 260. doi: 10.1186/s12967-016-1020-8.</mixed-citation><mixed-citation xml:lang="en">Zheng S, Shi S, Ren X, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. Journal of translational medicine. 2016 Sep 7; 14(1): 260. doi: 10.1186/s12967-016-1020-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Er LK, Wu S, Chou HH. et al. Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals. PLoS One. 20161;11(3):e0149731. doi: 10.1371/journal.pone.0149731.</mixed-citation><mixed-citation xml:lang="en">Er LK, Wu S, Chou HH. et al. Triglyceride Glucose-Body Mass Index Is a Simple and Clinically Useful Surrogate Marker for Insulin Resistance in Nondiabetic Individuals. PLoS One. 20161;11(3):e0149731. doi: 10.1371/journal.pone.0149731.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Возможности и варианты суррогатной оценки инсулинорезистентности. Ожирение и метаболизм. 2019; 16(1): 27-32. doi: 10.14341/omet10082</mixed-citation><mixed-citation xml:lang="en">Ruyatkina LA, Ruyatkin DS, Iskhakova IS. Opportunities and options for surrogate assessment of insulin resistance. Obesity and metabolism. 2019; 16(1): 27-32. doi: 10.14341/omet10082 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 4083.doi: 10.15829/1560-4071-2020-4083</mixed-citation><mixed-citation xml:lang="en">Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta psychiatrica Scandinavica. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</mixed-citation><mixed-citation xml:lang="en">Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta psychiatrica Scandinavica. 1983;67(6):361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Smets E.M., Garssen B., Bonke B., et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of psychosomatic research. 1995; 39(3):315-25 https://doi.org/10.1016/0022-3999(94)00125-o</mixed-citation><mixed-citation xml:lang="en">Smets E.M., Garssen B., Bonke B., et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of psychosomatic research. 1995; 39(3):315-25 https://doi.org/10.1016/0022-3999(94)00125-o</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Fox, C. S., Massaro, J. M., Hoffmann, U. et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1): 39–48. doi: 10.1161/CIRCULATIONAHA.106.675355</mixed-citation><mixed-citation xml:lang="en">Fox, C. S., Massaro, J. M., Hoffmann, U. et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116(1): 39–48. doi: 10.1161/CIRCULATIONAHA.106.675355</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord. 2014;12(1):31– 42. doi: 10.1089/met.2013.0107;</mixed-citation><mixed-citation xml:lang="en">Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord. 2014;12(1):31– 42. doi: 10.1089/met.2013.0107;</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Pou KM, Massaro JM, Hoffmann U. et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007; 116(11): 1234–1241. doi: 10.1161/CIRCULATIONAHA.107.710509</mixed-citation><mixed-citation xml:lang="en">Pou KM, Massaro JM, Hoffmann U. et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007; 116(11): 1234–1241. doi: 10.1161/CIRCULATIONAHA.107.710509</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Garg, S., Kim, L., Whitaker, M. et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1-30, 2020. MMWR. Morbidity and mortality weekly report, 2020; 69(15): 458-464. doi: 10.15585/mmwr.mm6915e3.</mixed-citation><mixed-citation xml:lang="en">Garg, S., Kim, L., Whitaker, M. et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1-30, 2020. MMWR. Morbidity and mortality weekly report, 2020; 69(15): 458-464. doi: 10.15585/mmwr.mm6915e3.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 (АКТИВ SARS-CoV-2)». Предварительные данные (6 месяцев наблюдения). Российский кардиологический журнал. 2021; 26(10): 4708. doi: 10.15829/1560-407].</mixed-citation><mixed-citation xml:lang="en">Arutyunov G.P., Tarlovskaya Е.I., Arutyunov A.G. Clinical features of post-COVID-19 period. Results of the international register «Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARSCoV-2)». Data from 6-month follow-up. Russian Journal of Cardiology. 2021; 26(10): 4708. DOI: 10.15829/1560-4071-2021-4708. [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Favre G, Legueult K, Pradier C, et al. Visceral fat is associated to the severity of COVID-19. Metabolism. 2021; 115: 154440. doi: 10.1016/j.metabol.2020.154440</mixed-citation><mixed-citation xml:lang="en">Favre G, Legueult K, Pradier C, et al. Visceral fat is associated to the severity of COVID-19. Metabolism. 2021; 115: 154440. doi: 10.1016/j.metabol.2020.154440</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Misumi I, Starmer J, Uchimura T. et al. Obesity Expands tinct Population of T Cells in Adipose Tissue and Increases Vulnerability to Infection. Cell Rep. 2019;27(2):514–524.e5. doi: 10.1016/j.celrep.2019.03.030</mixed-citation><mixed-citation xml:lang="en">Misumi I, Starmer J, Uchimura T. et al. Obesity Expands tinct Population of T Cells in Adipose Tissue and Increases Vulnerability to Infection. Cell Rep. 2019;27(2):514–524.e5. doi: 10.1016/j.celrep.2019.03.030</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Loosen S.H., Jensen B.O., Tanislav C. et al. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. Infection. 2022; 50(5): 1165–1170. doi: 10.1007/s15010-022-01784-0</mixed-citation><mixed-citation xml:lang="en">Loosen S.H., Jensen B.O., Tanislav C. et al. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients. Infection. 2022; 50(5): 1165–1170. doi: 10.1007/s15010-022-01784-0</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Либис Р.А., Исаева Е.Н. Возможность применения индекса висцерального ожирения в диагностике метаболического синдрома и прогнозировании риска его осложнений. Российский кардиологический журнал. 2014; (9): 48-53. doi: 10.15829/1560-4071-2014-9-48-53</mixed-citation><mixed-citation xml:lang="en">Libis R.A., Isaeva E.N. Opportunities for the use of visceral obesity index in metabolic syndrome diagnostics and prognosis of its complication risk. Russian Journal of Cardiology. 2014; (9): 48-53. https://doi.org/10.15829/1560-4071-2014-9-48-53 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Leite N.N., Cota B.C., Gotine AREM, et al. Visceral adiposity index is positively associated with blood pressure: A systematic review. Obesity research &amp; clinical practice. 2021; 15(6): 546-556. doi: 10.1016/j.orcp.2021.10.001.</mixed-citation><mixed-citation xml:lang="en">Leite N.N., Cota B.C., Gotine AREM, et al. Visceral adiposity index is positively associated with blood pressure: A systematic review. Obesity research &amp; clinical practice. 2021; 15(6): 546-556. doi: 10.1016/j.orcp.2021.10.001.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов А.Г., Тарловская Е.И., Галстян Г.Р., и др. Влияние ИМТ на острый период COVID-19 и риски, формирующиеся в течение года после выписки. Находки субанализа регистров АКТИВ и АКТИВ 2. Проблемы Эндокринологии. 2022; 68(6): 89-109. https://doi.org/10.14341/probl13165</mixed-citation><mixed-citation xml:lang="en">Arutyunov A.G., Tarlovskaya E.I., Galstyan G.R., et al. The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries. Problems of Endocrinology. 2022;68(6):89-109. https://doi.org/10.14341/probl13165 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Кононова А.А., Сурхаева А.А., Минаков А.А., и др. Характер нарушений углеводного обмена у пациентов, получавших лечение по поводу пневмонии, вызванной SARS-CоV-2. Известия Российской военно-медицинской академии. 2022; 41(S2): 215-221.</mixed-citation><mixed-citation xml:lang="en">Kononova A.A., Surkhaeva A.A., Minakov A.A., et al. Risk factors for carbohydrate metabolism disorders in covid-19. Russian Military Medical Academy Reports.2022;41(S2):215–221. EDN XUANLT [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Салухов В.В., Арутюнов Г.П., Тарловская Е.И. и др. Влияние нарушений углеводного обмена на ранние и отдаленные клинические исходы у пациентов с COVID-19 по данным регистров АКТИВ и АКТИВ 2. Проблемы Эндокринологии. 2023; 69(1): 36-49. https://doi.org/10.14341/probl13175</mixed-citation><mixed-citation xml:lang="en">Salukhov V.V., Arutyunov G.P., Tarlovskaya E.I., et al. The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries. Problems of Endocrinology. 2023; 69(1): 36-49. https://doi.org/10.14341/probl13175 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Ojo O., Wang X.H., Ojo O.O. et al. The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and MetaAnalysis. Int J Environ Res Public Health. 2022; 19(3): 1095. doi: 10.3390/ijerph19031095;</mixed-citation><mixed-citation xml:lang="en">Ojo O., Wang X.H., Ojo O.O. et al. The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and MetaAnalysis. Int J Environ Res Public Health. 2022; 19(3): 1095. doi: 10.3390/ijerph19031095;</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Brutsaert, D. L., Sys, S. U., Gillebert, T. C. Diastolic failure: Pathophysiology and therapeutic implications. Journal of the American College of Cardiology.1993;22(1):318–325. doi: 10.1016/0735-1097(93)90850-z.</mixed-citation><mixed-citation xml:lang="en">Brutsaert, D. L., Sys, S. U., Gillebert, T. C. Diastolic failure: Pathophysiology and therapeutic implications. Journal of the American College of Cardiology.1993;22(1):318–325. doi: 10.1016/0735-1097(93)90850-z.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Чистякова М.В., Зайцев Д.Н., Говорин А.В., и др. «Постковидный» синдром: морфо-функциональные изменения и нарушения ритма сердца. Российский кардиологический журнал. 2021; 26(7): 4485. doi: 10.15829/1560-4071-2021-4485</mixed-citation><mixed-citation xml:lang="en">Chistyakova M.V., Zaitsev D.N., Govorin A.V., et al. PostCOVID-19 syndrome: morpho-functional abnormalities of the heart and arrhythmias. Russian Journal of Cardiology. 2021; 26(7): 4485. doi: 10.15829/1560-4071-2021-4485[in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ramadan M.S., Bertolino L., Zampino R., et al. Monaldi Hospital Cardiovascular Infection Study Group. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021; 27(9): 1250–1261. DOI: 10.1016/j.cmi.2021.06.015.</mixed-citation><mixed-citation xml:lang="en">Ramadan M.S., Bertolino L., Zampino R., et al. Monaldi Hospital Cardiovascular Infection Study Group. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021; 27(9): 1250–1261. DOI: 10.1016/j.cmi.2021.06.015.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chen, L., Li, X., Chen, M., et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research, 116(6), 1097–1100. https://doi.org/10.1093/cvr/cvaa078</mixed-citation><mixed-citation xml:lang="en">Chen, L., Li, X., Chen, M., et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular research, 116(6), 1097–1100. https://doi.org/10.1093/cvr/cvaa078</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Потешкина Н.Г., Лысенко М.А., Ковалевская Е.А. и др. Кардиальное повреждение у пациентов с коронавирусной инфекцией COVID-19. Артериальная гипертензия. 2020;26(3):277-87. doi: 10.18705/1607-419X-2020-26-3-277-287</mixed-citation><mixed-citation xml:lang="en">Poteshkina NG, Lysenko MA, Kovalevskaya EA, et al. Cardiac damage in patients with COVID-19 coronavirus infection. Arterial Hypertension. 2020;26(3):277-87 [in Russian].</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Krishnamoorthy P, Croft LB, Ro R, et al. Biventricular strain by speckle tracking echocardiography in COVID-19: findings and possible prognostic implications. Future Cardiology. 2021 Jul; 17(4): 663-667. doi: 10.2217/fca-2020-0100. Epub 2020 Aug 4..</mixed-citation><mixed-citation xml:lang="en">Krishnamoorthy P, Croft LB, Ro R, et al. Biventricular strain by speckle tracking echocardiography in COVID-19: findings and possible prognostic implications. Future Cardiology. 2021 Jul; 17(4): 663-667. doi: 10.2217/fca-2020-0100. Epub 2020 Aug 4..</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Akhmerov, A., &amp; Marbán, E. (2020). COVID-19 and the Heart. Circulation research. 2020 May 8; 126(10): 1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.</mixed-citation><mixed-citation xml:lang="en">Akhmerov, A., &amp; Marbán, E. (2020). COVID-19 and the Heart. Circulation research. 2020 May 8; 126(10): 1443-1455. doi: 10.1161/CIRCRESAHA.120.317055. Epub 2020 Apr 7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
